Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.

Lima, Bárbara; Abreu, Miguel Henriques; Sousa, Susana; Bartosch, Carla; Pereira, Deolinda

Lima, Bárbara; Abreu, Miguel Henriques; Sousa, Susana; Bartosch, Carla; Pereira, Deolinda.

Afiliación

Lima B; Department of Medical Oncology, Hospital Senhora da Oliveira, Guimarães, Portugal.
Abreu MH; Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Sousa S; Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Bartosch C; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Pereira D; Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.

Gynecol Oncol Rep ; 40: 100942, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35242981

Palabras clave

BRAF mutation; Combination treatment; Dabrafenib; Low-grade serous ovarian cancer; Trametinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gynecol Oncol Rep Año: 2022 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google